Insulin Therapy Center

I have type 1 diabetes and have been living with it for the past 11 years. I take daily insulin injections to stay alive and well. A couple of years ago, I had a very frustrating incident when my insulin stopped working. I began injecting loads of insulin, and even with multiple doses my blood glucose wouldn’t drop.

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

One long-acting insulin may be better at controlling glycemic variations.

In this week's Homerun Slides, beta cell failure in type 2 diabetes mellitus and the concept of glucotoxicity.

n this week's Homerun Slides, finding the common ground between - and possible path to treatment of - hyperglycemia and the causes of vascular disease.

In this week's Homerun Slides, a continued explanation of insulin resistance and its causes, as well as its impact on hyperinsulinemia.

In this week's Homerun Slides, the effects of hyperinsulinism.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.